VANCOUVER, BC, Sept. 22, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it has been included in the new AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol "PSIL" (the "ETF").
PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. The ETF is actively managed and concentrates its investments in companies receiving the majority of their net revenue or allocating the majority of their assets from psychedelic drugs.
Kelsey Ramsden, MINDCURE President and CEO, said: "MINDCURE's inclusion in the AdvisorShares Psychedelics ETF is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. MINDCURE is proud to be acknowledged as a leader in this emerging space and our inclusion in the ETF will increase investor awareness to the Company and the benefits of psychedelic treatment methods to improve mental health."
You can find additional information on the AdvisorShares Psychedelics ETF here.
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.